Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post about an article on X:
“Ultrasensitive ctDNA in early stage NSCLC.
TRACERx whole genome, tumor informed ctDNA analysis (2,994 samples, 431 pts).
- Detection <80 ppm pre and post surgery was highly prognostic.
- Combined pre and postoperative ctDNA defined an intermediate risk group.
- ctDNA clearance during adjuvant therapy associated with improved outcomes.
- Longitudinal kinetics informed timing and pattern of relapse.”
Title: Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction
Authors: James R M Black, Takahiro Karasaki, Charles W Abbott, Bailiang Li, Selvaraju Veeriah, Maise Al Bakir, Wing Kin Liu, Ariana Huebner, Carlos Martínez-Ruiz, Piotr Pawlik, David A Moore, Daniele Marinelli, Oliver Shutkever, Cian Murphy, Lydia Y Liu, Charlotte Grieco, Karen Grimes, Fabio C P Navarro, Rachel Marty Pyke, Gabor Bartha, Kathleen C Keough, Steven Dea, Neeraja Ravi, John Lyle, Jason Harris, Katherine D Brown, Fiona H Blackhall, Fatemah Hassani, Dean A Fennell, Nicholas McGranahan, Jacqui A Shaw, Christopher Abbosh; TRACERx Consortium; Allan Hackshaw, Mariam Jamal-Hanjani, Alexander M Frankell, Sean M Boyle, Richard O Chen, Charles Swanton
More posts featuring Diego A. Díaz-García on OncoDaily.
